For the Inventor, By the Inventor

Enter assignee name

Poxel

Calculating rank

USPTO Granted Patents = 13

% Expired Patents = 23.1

CIPO Patents = 2

EPO Patents = 14

Forward Citations = 28

Loading Chart...

Loading Chart...

32 inventors (with patents filed for the assignee):

Daniel Cravo (9 out of 26 patents)

Sophie Hallakou-Bozec (7 out of 14 patents)

Sébastien Bolze (6 out of 11 patents)

4. Pascale Fouqueray (3 out of 3 patents)

5. Jean-Denis Durand (2 out of 6 patents)

6. Amaury Patin (2 out of 10 patents)

7. Franck F Lepifre (2 out of 12 patents)

8. Patrice Andre (2 out of 37 patents)

9. Pauline Radreau (2 out of 2 patents)

10. Vincent Lotteau (2 out of 10 patents)

11. Marine Gilardone (2 out of 2 patents)

12. Christine G Charon (2 out of 28 patents)

13. Laurent Faveriel (2 out of 2 patents)

14. Didier Mesangeau (2 out of 13 patents)

15. Matthias Helmreich (2 out of 3 patents)

13 patents: Sort by Forward Citations

1. 12319700 - Monohydrate potassium salt of a thienopyridone derivative and its preparation process (2025-06-03),

2. 12310949 - Use of a thienopyridone derivative in the treatment of autosomal dominant polycystic kidney disease (ADPKD) (2025-05-27),

3. 11850238 - Use of a thienopyridone derivative in the treatment of adrenoleukodystrophy or adrenomyeloneuropathy (2023-12-26),

4. 10071108 - Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection (2018-09-11),

5. 9895380 - Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection (2018-02-20),

6. 9365584 - Thieno [2,3-B] pyridinedione activators of AMPK and therapeutic uses thereof (2016-06-14),

7. 9284329 - Thienopyridone derivatives useful as activators of AMPK (2016-03-15),

8. 9271984 - Treatment of type 1 diabetes (2016-03-01),

9. 9035048 - Tetrahydrotriazine compounds for treating diseases associated with AMPK activity (2015-05-19),

10. 8937066 - Amino derivatives of dihydro-1,3,5-triazine used in the treatment of ischemia and/or reperfusion related diseases (2015-01-20),

11. 8846911 - Process of isolating enantiomer components from enantiomer mixtures by particle-size-controlled crystallization (2014-09-30),

12. 8742103 - Separation of triazine derivatives enantiomers using tartaric acid (2014-06-03),

13. 8742102 - Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization (2014-06-03),

Company Overview

Poxel is a biopharmaceutical company based in Lyon, France, specializing in the development of innovative therapies for metabolic diseases, particularly diabetes and obesity. The company focuses on advancing its proprietary drug candidates through rigorous research and development, leveraging expertise in pharmacology and metabolic science. Poxel aims to address unmet medical needs by creating effective treatments that improve patient outcomes and enhance quality of life in the field of metabolic health.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

13 Patents

#30 in Lyon

#1,399 in France

#45,104 in the World

Poxel

Forward Citations = 28

32 inventors:

Daniel Cravo (9 out of 26 patents)

Sophie Hallakou-Bozec (7 out of 14 patents)

Sébastien Bolze (6 out of 11 patents)

4. Pascale Fouqueray (3 out of 3 patents)

5. Jean-Denis Durand (2 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Poxel. Retrieved from https://idiyas.com/company/poxel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…